Essence Securities Keeps Their Buy Rating on Duality Biotherapeutics, Inc. (9606)Tip Ranks·1 day ago, 05:07 AM09606-1.53%
The Algorithm's Leftovers: What 10 Orphaned Stocks Reveal About Hong Kong's Market AnxietyGlobal Report·Sep 2 at 10:13 AM011500.00%018660.00%
Weekly Recap | DUALITYBIO-B +5.65%, most brokers rate it buyWeekly Review·Aug 29 at 04:59 AM09606-1.53%
Duality Biotherapeutics FY26 H1 loss narrows to RMB 917.55 million; revenue drops 82.16% to RMB 219.33 millionPUBT·Aug 28 at 10:34 AM09606-1.53%
DualityBio climbs 5% on ADC drug deal with Roche's GenentechHK Stock Market Update·Aug 28 at 01:36 AM09606-1.53%
Duality Biotherapeutics Strikes Billion-Dollar ADC Collaboration with GenentechTip Ranks·Aug 27 at 11:37 PM09606-1.53%RHHBY-0.46%
Unbundling and Rebundling: How 10 Hong Kong Stocks Are Navigating the New Value ChainGlobal Report·Aug 25 at 11:33 AM02150-2.94%06896+0.44%
MedicaBiologics-B climbs 5% during regular tradingHK Stock Market Update·Aug 20 at 01:38 AM09606-1.53%
Harbin Electric's 19% Revenue Jump Contrasts With Nayuki's Margin Squeeze in Uneven HK Equities RunGlobal Report·Aug 18 at 10:12 AM08527-12.86%08148+2.01%
UBS Initiates Coverage on DUALITYBIO-B with Buy Rating, TP at HKD320AASTOCKS News·Aug 14 at 10:11 AM09606-1.53%
Hong Kong Rotations: AI Hardware IPOs Boom While Consumer Giants PivotGlobal Report·Aug 11 at 09:43 AM02282+2.47%07656-5.45%
Duality Biologics climbs nearly 7% on DB-1311 breakthrough therapy nodHK Stock Market Update·Aug 11 at 05:26 AM09606-1.53%
Duality Biologics gains 8% in Hong Kong after DB-1311 breakthrough nodHK Stock Market Update·Aug 11 at 05:24 AM09606-1.53%